<DOC>
	<DOCNO>NCT02667158</DOCNO>
	<brief_summary>To evaluate reason patient go one prescriber one pharmacy obtain prescription opioids ass whether percentage patient report misuse , abuse and/or diversion increase across defined category doctor/pharmacy shop define Study 4A .</brief_summary>
	<brief_title>A Survey Eval Relation Between Doctor/Pharmacy Shopping Outcomes Suggestive Misuse , Abuse and/or Diversion</brief_title>
	<detailed_description>Based review literature , Food Drug Administration ( FDA ) conclude data need regard serious risk misuse , abuse , addiction , overdose , death associate long-term use extend release/long acting ( ER/LA ) opioid analgesic . Thus , FDA require ER/LA opioid analgesic drug sponsor conduct post-marketing study assess risk . The four observational post-marketing requirement ( PMR ) study label Study # 2065-1 , Study # 2065-2 , Study # 2065-3 , Study # 2065-4 . The objective PMR Study # 2065-4 define validate doctor/pharmacy shop outcome suggestive misuse , diversion , abuse and/or addiction . Study # 2065-4 consists three sub-studies , Study 4A , Study 4B , Study 4C . In current study ( # 2065-4 sub-study , Study 4B ) , association doctor/pharmacy shop behavior misuse , diversion abuse assess survey patient within priori define four category shop behavior . The four category shop behavior identify define Study 4A apply Study 4B . Asking patient directly behavior relate misuse abuse provide u patient 's perspective unavailable Study 4A . Surveying patient regard misuse abuse require use instrument undergone validation process ensure misuse abuse measure . Study 4B utilize Prescription Opioid Misuse Abuse Questionnaire ( POMAQ ) validate PMR Study # 2065-2A . An administrative claim database use identify eligible patient population use pharmacy claim immediate release ( IR ) ER/LA opioid analgesic determine number prescribers number pharmacy visit . Consenting patient ask complete online survey include POMAQ self-report behavior misuse , abuse and/or diversion . It hypothesize likelihood doctor/pharmacy shop behavior increase risk misuse , abuse and/or diversion .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<criteria>Patients must meet follow inclusion criterion : 1 . At least two pharmacy claim IR ER/LA opioid analgesic recent 18 month claim data . 2 . Based claim recent 18 month data , meet classification criterion one four priori define doctor/pharmacy shopping category . 3 . Currently active , commerciallyinsured , survey eligible medical pharmacy benefit health plan include HealthCore Integrated Research Database ( HIRD ) time sample list extract . 4 . At least 18 year age date first IR ER/LA opioid dispense recent 18 month claim data . 5 . A telephone number address know HealthCore . 1 . Patients appear HealthCore `` Donotcall '' list . 2 . Patients known history abuse 3 . Patients indicate read pertinent aspect study agree participate . 4 . Patients fail validate name and/or date birth 5 . Patients unable understand survey question design ( e.g. , nonEnglish speaking , etc. ) . 6 . Patients fail studyspecific screening question .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>